BRIGHT

Fortitude Re Donates $100,000 to 100 Black Men of Middle Tennessee to support academic programs for Black male students

Retrieved on: 
Thursday, February 8, 2024
DEI (Diversity, Equity and Inclusion), Other Philanthropy, Insurance, Other Education, Professional Services, Philanthropy, Education, Foundation, Fortitude, Student, Empowerment, Organization, Multimedia, Male, BRIGHT

Fortitude Reinsurance Company Ltd., (“Fortitude Re”) today announced a $100,000 donation to 100 Black Men of Middle Tennessee, Inc., a nonprofit organization that provides resources to further academic and social development of Black male students.

Key Points: 
  • Fortitude Reinsurance Company Ltd., (“Fortitude Re”) today announced a $100,000 donation to 100 Black Men of Middle Tennessee, Inc., a nonprofit organization that provides resources to further academic and social development of Black male students.
  • View the full release here: https://www.businesswire.com/news/home/20240208770002/en/
    Latasha Brown and Conselola Brown, members of Fortitude Re's BRIGHT ERG for Black professionals, are joined by 100 Black Men of Middle TN leadership and students served by the nonprofit for the check presentation.
  • The remaining funds will support academic enrichment initiatives including college and career readiness programs.
  • The organization is an affiliate of 100 Black Men of America, Inc., a service organization chartered in 1986 with a commitment to improve the academic and social proficiency of inner-city youth.

Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

Retrieved on: 
Friday, February 2, 2024
CHI, CCNR, Stroke, BRIGHT, Patient, Tissue plasminogen activator, Brain, Therapy, Hope, Doctor of Philosophy, U.S. FDA, Pharmaceutical industry

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.

Key Points: 
  • TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.
  • Lumosa and CHI Memorial aim to redefine what is possible in preventing stroke disability and impairment.
  • In December 2023, CHI Memorial achieved a significant milestone by enrolling the first U.S. patient in the Lumosa 203, double-blinded stroke study.
  • Lumosa and CHI Memorial are committed to advancing medical innovation and improving the lives of stroke patients worldwide.

Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

Retrieved on: 
Friday, February 2, 2024
CHI, CCNR, Stroke, BRIGHT, Patient, Tissue plasminogen activator, Brain, Therapy, Hope, Doctor of Philosophy, U.S. FDA, Pharmaceutical industry

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.

Key Points: 
  • TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.
  • Lumosa and CHI Memorial aim to redefine what is possible in preventing stroke disability and impairment.
  • In December 2023, CHI Memorial achieved a significant milestone by enrolling the first U.S. patient in the Lumosa 203, double-blinded stroke study.
  • Lumosa and CHI Memorial are committed to advancing medical innovation and improving the lives of stroke patients worldwide.

Apartments.com Releases Rent Growth Report for Third Quarter of 2023

Retrieved on: 
Friday, October 6, 2023
Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, BRIGHT, Multimedia, Risk, TruAmerica Multifamily, Growth, Weakness, CoStar Group, National Directorate of Security, Plague, Beauty salon, Commercial property, Employment agency, Tourism, Sun Belt

Today, Apartments.com – a CoStar Group online marketplace – published an in-depth report of multifamily rent growth trends for the third quarter of 2023.

Key Points: 
  • Today, Apartments.com – a CoStar Group online marketplace – published an in-depth report of multifamily rent growth trends for the third quarter of 2023.
  • Imbalances between supply and demand continue to plague the once fast-growing Sun Belt markets, while markets in the Northeast and Midwest round out the top rent growth leaders.
  • Upward pressure on vacancy has led year-over-year asking rent growth to decelerate from 1.3% to 0.8% over the last 90 days.
  • Many of these markets finished the third quarter with negative year-over-year rent growth, particularly Atlanta and Austin, which witnessed their rent growth vanish from 17.0% at the end of 2021 to negative 3.1% and negative 4.8% respectively.

Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

Retrieved on: 
Friday, October 13, 2023
Health, Health care, Hot, Astellas Pharma, Committee for Medicinal Products for Human Use, CHMP, European, Fezolinetant, The Journal of Clinical Endocrinology and Metabolism, TSE, European Commission, Medication, Safety, European Medicines Agency, NKB, BRIGHT, EMA, MHRA, VMS, EC, Journal, Committee, Metabolism, Obstetrics and gynaecology, Gynaecology, Menopause, Civil service commission, Woman, Lancet, Hypothalamus, Pharmaceutical industry, Medical device

TOKYO, Oct. 13, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on October 12 adopted a positive opinion relating to the use of VEOZA™ (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.4 VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause.5,6  

Key Points: 
  • "Today's positive CHMP opinion marks another significant milestone for both fezolinetant and women's health.
  • We are excited to be another step closer to potentially providing a novel and important treatment option to individuals in Europe suffering from moderate to severe VMS associated with menopause."
  • The positive CHMP opinion is based on the results from the BRIGHT SKY™ program, which included three Phase 3 clinical trials that collectively enrolled over 3,000 individuals across Europe, the U.S. and Canada.
  • Astellas has already reflected the impact from this result in its financial forecast of the current fiscal year ending March 31, 2024.

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

Retrieved on: 
Friday, May 12, 2023
NKB, UNC School of Medicine, Hot, VMS, Obstetrics, Fezolinetant, Woman, Brain, Temperature, Hormone, BRIGHT, Patient, Estrogen, Menopause, Neurokinin B, Gynaecology, Biology, Health, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, TSE, Full, Pharmaceutical industry, Birth control, EU, Astellas Pharma

TOKYO, May 12, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause1 on May 12. VEOZAH is the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved to treat VMS due to menopause.

Key Points: 
  • VEOZAH is the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved to treat VMS due to menopause.
  • I'm excited to know that patients will have the option to choose this nonhormonal treatment."
  • Before menopause, there is a balance between estrogens (hormones made by a woman's ovaries) and neurokinin B (NKB), a brain chemical.
  • Astellas has already reflected the impact from this approval in its financial forecast of the current fiscal year ending March 31, 2024.

Mixed Performance in the Latest CoStar Composite Price Indices

Retrieved on: 
Friday, April 28, 2023
Residential Building & Real Estate, Commercial Building & Real Estate, Urban Planning, Construction & Property, EQUAL, INDEX, FOUR, LAND, Multimedia, PRIME, Sale, Index, BRIGHT, Composite index, Bond credit rating, FIRST, Composite, Water, Acceleration, Growth, WITH, Cryptocurrency, Drug, Video game, Tourism

View the full release here: https://www.businesswire.com/news/home/20230428005331/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230428005331/en/
    U.S. COMPOSITE PRICE INDICES WERE MIXED IN MARCH 2023.
  • THE EQUAL-WEIGHTED GENERAL COMMERCIAL COMPOSITE PRICE INDEX OUTPACED INVESTMENT GRADE IN MARCH 2023.
  • Including land and hospitality, the property type indices’ average price growth treaded water in the first quarter of 2023, up just 0.2%.
  • Three property sectors in the midwestern indices soured performance with negative pricing over the prior year.

ENTREPRENEUR UNIVERSE BRIGHT GROUP Announces Effectiveness of Form S-1 Resale Registration Statement

Retrieved on: 
Tuesday, February 7, 2023
Sale, Prospectus, BRIGHT, Securities and Exchange Commission (Philippines), OTC Markets Group, UNIVERSE, Security (finance)

The selling stockholders identified in the prospectus are offering on a resale basis an aggregate of 140,000,000 shares of the Company's common stock.

Key Points: 
  • The selling stockholders identified in the prospectus are offering on a resale basis an aggregate of 140,000,000 shares of the Company's common stock.
  • The securities registered pursuant to the registration statement are not required to be sold, and the registration of the securities does not necessarily indicate that any selling stockholder intends to sell its securities.
  • The registration statement, while effective, permits resale of the securities covered by the registration statement, subject to the satisfaction by the seller of the securities with the prospectus delivery requirements of the Securities Act of 1933.
  • The offering of the securities covered by the registration statement may only be made by means of a prospectus.

InventHelp Inventor Develops Improved Design for Headphones (CPC-671)

Retrieved on: 
Friday, December 16, 2022
DEPT, Noise, BRIGHT, Sound, Sale, Multimedia, Cassette tape

The invention provides an improved design for headphones.

Key Points: 
  • The invention provides an improved design for headphones.
  • The invention features an inventive design that is easy to use so it is ideal for music/media enthusiasts.
  • The original design was submitted to the Connecticut sales office of InventHelp.
  • 21-CPC-671, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

InventHelp Inventor Develops Improved Design for Headphones (CPC-671)

Retrieved on: 
Friday, December 2, 2022
Multimedia, Noise, Sound, Sale, DEPT, BRIGHT, Cassette tape

The invention provides an improved design for headphones.

Key Points: 
  • The invention provides an improved design for headphones.
  • The invention features an inventive design that is easy to use so it is ideal for music/media enthusiasts.
  • The original design was submitted to the Connecticut sales office of InventHelp.
  • 21-CPC-671, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.